United States · Funded startup

Who invested in Braeburn

One round we have observed, with the 7 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$110Mraised across 1 round since 2018, from 1 source

Latest round
Debt, $110MJan 2018
Investors
7
See who backed them

The rounds

  1. Jan 2018
    Debt$110M

    Reported by FinSMEs

Founders and team

From Braeburn's own website: 5 on the team.

  • Mike DerkaczPresident & CEO
  • Joshua CohenChief Medical Officer
  • Lou RiciglianoChief Financial Officer
  • Meredith TaylorChief Compliance Officer
  • Brian HirschGeneral Counsel

Everyone who backed them

RA Capital ManagementPrivate equity1round
LD CapitalVC firm1round
DeerfieldVC firm1round
Apple Tree PartnersVC firm1round
New Leafno record of our own yet1round
Rock Springsno record of our own yet1round
Wellington Capital Management/ Avistano record of our own yet1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Braeburn

Who invested in Braeburn?

Braeburn's investors include RA Capital Management, LD Capital, Deerfield, Apple Tree Partners and New Leaf, and 2 more on record.

How much has Braeburn raised?

Braeburn has raised $110M across 1 round since 2018.

When did Braeburn last raise?

Braeburn's most recent round was a Debt of $110M in Jan 2018.

What was Braeburn's biggest round?

Its most recent round, $110M in Jan 2018, is also its largest on record.

Who backed Braeburn first?

Braeburn's first round on record, in Jan 2018, was backed by RA Capital Management, LD Capital and Deerfield and 4 others.

What stage is Braeburn at?

Braeburn's latest named round is a Debt, in Jan 2018.

Where is Braeburn based?

Braeburn is based in the United States.

Companies like Braeburn

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.